Later this month, MDoutlook will release results from the latest wave of their global leadership study.
Using ONCpulse™, we engaged with a robust sample of oncologists located in the United States and Europe. The research objectives were to:
- Define the meaning of “corporate leadership” to the oncology community
- Reveal the leaders in oncology and ImmunoOncology (IO) and to compare / contrast how companies are evaluated by oncologists
- Assess current drivers & barriers to ImmunoOncology treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space
Across tumor types, BMS were rated as the top ImmunoOncology leader in 9 out of the 12 areas covered. Oncologists favored Roche & Merck highest in breast cancer (Roche); bladder cancer (Roche & Merck) and NSCLC (Merck).
Oncologists chose to rate leadership across a greater number of companies in the broader oncology arena compared to a tighter list of companies they rated in ImmunoOncology.
Seventy percent of US oncologists viewed leadership success across tumor types than in any one specific area (30% respondents). This view was stronger when compared to the split picture (49% vs 51% respectively) presented by EU-based oncologists.
More information about the 2019 Leadership Study will become available as we publish the read-out results. Please contact us if you wish to be included in the distribution of the study.